

A Randomized Controlled Trial Evaluating Duloxetine on Post-Operative Outcomes following Primary Total Knee Arthroplasty

JaeWon Yang¹, Steven Kurina², Matthew Weintraub³, Anne DeBenedetti²,
Tad Gerlinger², Vasili Karas², Denis Nam², Craig Della Valle²

¹ University of Washington, Seattle, WA, ² Rush University, Chicago, IL, ³ Mayo Clinic, Rochester, MN
jyang92@uw.edu

Disclosures: J. Yang: None. S. Kurina: None. M. Weintraub: None. A. DeBenedetti: None. T. Gerlinger: 1; Smith and Nephew. 3B; Smith and Nephew. 5; Smith and Nephew. V. Karas: 1; Corin U.S.A.. 3B; Corin U.S.A., Stryker. 5; Stryker. D. Nam: 3B; KCI, Stryker. 5; KCI, Zimmer. C. Della Valle: 1; BD, Smith & Nephew, Zimmer. 3B; DePuy, A Johnson & Johnson Company, Zimmer. 4; Navbit, Parvizi Surgical Innovations. 5; Smith & Nephew, Stryker, Zimmer. 7B; SLACK Incorporated. 8; Orthopedics Today, SLACK Incorporated, Wolters Kluwer Health. 9; Arthritis Foundation, Knee Society, MidAmerica Orthopaedic Association.

INTRODUCTION: Utilizing serotonin and norepinephrine reuptake inhibitors (SNRIs such as Duloxetine) to treat musculoskeletal pain has recently garnered interest. However, current literature remains limited with mixed results reported and no randomized trials. The purpose of this study was to evaluate the effect of duloxetine on post-operative pain, function, and opioid consumption in patients undergoing primary total knee arthroplasty (TKA).

METHODS: Patients undergoing primary TKA were randomized to receive either duloxetine (30 mg) or placebo daily one week prior to surgery until 6 weeks post-operatively after screening found them not to meet criteria for central sensitization. Daily morphine milliequivalents (MME), hours of sleep, and subjective measures of feeling well rested were assessed for two weeks post-operatively. VAS and KOOS were assessed at six-weeks following surgery. An a priori power analysis determined that 44 patients were required in each cohort to detect a minimally clinically important difference of 2 points in VAS pain scores.

RESULTS: 102 Patients were enrolled with 58 randomized to the duloxetine cohort and 44 to placebo. Demographics were similar between groups, reflecting successful randomization. In the two weeks following surgery, patients in the duloxetine group reported feeling significantly more well-rested on a 10-point scale (7.0 vs 6.3, $p=0.04$). There were no differences in MME consumption (duloxetine: 351 vs placebo: 359, $p=0.36$) or average nightly hours of sleep (duloxetine: 6.5 vs placebo: 6.9, $p=0.11$). The duloxetine group had greater KOOS scores at six weeks postoperatively (72 vs 67, $p=0.01$). There was no difference in VAS pain scores (2.0 vs 2.5, $p=0.16$).

DISCUSSION: Patients taking duloxetine felt significantly more well rested immediately following TKA and had superior KOOS scores at 6 weeks, although this difference may not be clinically important. Further research is required to investigate the benefit of duloxetine and SNRIs following TKA in patients without central sensitization.

SIGNIFICANCE/CLINICAL RELEVANCE: Duloxetine and other serotonin and norepinephrine reuptake inhibitors (SNRIs) have recently garnered interest in treating osteoarthritis pain and pain following total joint arthroplasty. Our randomized controlled trial found that patients who received duloxetine following total knee arthroplasty subjectively felt better rested and had higher patient reported outcome measures, indicating that duloxetine and other SNRIs may have a role in post-operative pain control in the future.